1Thigpen T, Shingleton H, Homesley H, et al. Cis - platinum in treatment of advanced or recurrent squamous cell carci noma of the cevix: a phase Ⅱ study of the Gynecologic Oncology Group. Cancer, 1981, 48: 899-903.
2de Campo JM, PratA, Gil-MorenoA, et al. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol, 2008, 110 (Suppl 2): S72- 76.
3Castillo L, Etienne-Grimaldi MC, Fischel JL, et al. Pharmacological background of EGFR targeting. Ann Oncol, 2004, 15: 1007-1012.
4Bellone S, Palmieri M, Gokden M, et al. Selection of HER- 2/neupositive tumor ceils in early stage cervical cancer: implications for Herceptin - mediated therapy. Gynecol Oncol, 2003, 91: 231-240.
5Ciardiello F, Tortora G. A novel approach in the treatment of cancer, targeting the epidermal growth factor receptor. Clin Cancer Res, 2001, 7: 2958-2970.
7Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type- 1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab- mediated therapy in recurrent/metastatic disease. Gynecol Oncol, 2007, 106 : 513 -520.
8Meira DD, de Almeida VH, Mororo JS, et al, Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer, 2009, 101: 782-791.
9Goncalves A, Fabbro M, Lhomme C, et al. A phase Ⅱ trial to evaluate gefitinib as second - or third- line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol, 2008, 108: 42- 46.
10Kummel S, Heidecke H, Brock B, et al. Imatinib-a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study. Gynakol Geburtshilfliche Rundsch, 2008, 48: 94- 100.
同被引文献10
1Vistad I, Kristensen G B, Fossa S D, et al. Intestinalmalabsorption in long-term survivors of cervical cancer treated with radiotherapy [J]. Int J Radiat Oncol Biol Phys, 2009, 73(4): 1141-1147.
2Gee J, Lee I L, Grossman H B, et al. Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial ceils [J]. Urolo Oncol Semi Orig Invest, 2008, 26 (6) : 641-645.
3Husvik C, Khuu C, Bryne M, et al. PGE2 Production in Oral Cancer Cell Lines is COX-2-dependent [J]. J Dent Res, 2009, 88(2) : 164-169.
4Jung-Min O, Su-Hyeong K, Yun-Il L, et al. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells [J]. Carcinogenesis, 2009, 30: 141-149.
5Chang J C, Gross H M. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer [J]. Ame J Med,1984,76(4): 597-603.
6Grond S, Radbruch L, Meuser T, et al. Assessment and treatment of europathic cancer pain following WHO guidelines [Jl. Pain, 1999, 79(1): 15-20.
